EUVIMEDEUVIMED entdecken
Multizentrische Studie

Therapeutically Targetable Mutational Landscape of Anaplastic Thyroid Cancer

Murtaza Qazi iD, Muhammad Danyal Ahsan iD, Talar Telvizian, Samuel Laiacona, Nadir Ahmad, Terri McHugh

JCO Precision Oncology · 2026

DOI: 10.1200/po-25-00655 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Precision Oncology, 2026. Verfasst von Murtaza Qazi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Lankenau Medical Center, Wynnewood, PA. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Anaplastic thyroid cancer (ATC) is a rare and highly aggressive malignancy with limited treatment options. Currently, the only US Food and Drug Administration–approved targeted therapies for ATC are directed at BRAF V600E mutations and NTRK fusions. This study aimed to characterize the somatic pathogenic gene variant (PGV) landscape of ATC to identify additional potentially actionable pathways. METHODS We queried the American Association for Cancer Research Project GENIE database (v18.0) via cBioPortal for somatic PGVs in ATC tumors. This multi-institutional data set provides next-generation sequencing and clinical data across cancer types. Genes were grouped by pathway relevance: MAPK ( BRAF , KRAS , NRAS , EIF1AX ), PI3K/Akt/mTOR ( PIK3CA , PTEN , mTOR , AKT1/2/3 ), homologous recombination deficiency (HRD), and mismatch repair (MMR). RESULTS A total of 350 ATC tumor samples were analyzed. PGVs were identified in MAPK pathway genes in 57.7% of tumors, PI3K/Akt/mTOR pathway genes in 26.6%, HRD-associated genes in 8.0%, and MMR-associated genes in 3.7%. In total, 72.0% (252/350) of tumors harbored at least one PGV in one or more of these potentially targetable pathways. CONCLUSION Somatic PGVs in potentially targetable pathways were found in 72% of ATC tumors. Given the aggressiveness of ATC and the limited efficacy of current treatments, these findings support the rationale for biomarker-driven basket trials investigating the efficacy of targeted therapies in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid Carcinoma, AnaplasticThyroid NeoplasmsHumansMaleFemaleMiddle AgedAgedCohort StudiesMAP Kinase Signaling SystemMolecular Targeted TherapyOncogene FusionMutation

Autor:innen und Institutionen

  • Lankenau Medical Center, Wynnewood, PA.
  • Hospital of University of Pennsylvania, Philadelphia, PA.
  • Cooper University Hospital, Camden, NJ.

ORCID-Profile: Murtaza Qazi, Muhammad Danyal Ahsan

Zitieren

APA

Qazi, M., Ahsan, M. D., Telvizian, T., Laiacona, S., Ahmad, N., & McHugh, T. (2026). Therapeutically Targetable Mutational Landscape of Anaplastic Thyroid Cancer. JCO Precision Oncology. https://doi.org/10.1200/po-25-00655

Vancouver

Qazi M, Ahsan MD, Telvizian T, Laiacona S, Ahmad N, McHugh T. Therapeutically Targetable Mutational Landscape of Anaplastic Thyroid Cancer. JCO Precision Oncology. 2026. doi:10.1200/po-25-00655

BibTeX
@article{Qazi2026,
  author = {Qazi, Murtaza and Ahsan, Muhammad Danyal and Telvizian, Talar and Laiacona, Samuel and Ahmad, Nadir and McHugh, Terri},
  title = {Therapeutically Targetable Mutational Landscape of Anaplastic Thyroid Cancer},
  journal = {JCO Precision Oncology},
  year = {2026},
  doi = {10.1200/po-25-00655}
}
Kostenlos starten →